Log In
Print
BCIQ
Print
Print this Print this
 

Nitoman, Xenazine, tetrabenazine

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionSelective inhibitor of vesicular monoamine transporter (VMAT2)
Molecular Target Vesicular monoamine transporter 2 (VMAT2) (SLC18A2)
Mechanism of ActionVesicular monoamine transporter 2 inhibitor
Latest Stage of DevelopmentMarketed
IndicationHuntington's disease (HD)
Partner

Chiesi Farmaceutici S.p.A.; EUSA Pharma Inc.; H. Lundbeck A/S; Temmler Pharma GmbH & Co. KG
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today